Argentina, Australia, Brazil, Canada, Colombia, Czech Republic, Denmark, Germany, India, Italy, Kenya, Peru, Philippines, Poland, South Africa, Spain, United Kingdom, United States of America
MANAGE is a large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) vs placebo, and omeprazole (a proton-pump inhibitor) vs placebo in patients suffering myocardial injury after noncardiac surgery (MINS). MANAGE has a partial 2x2 factorial design and randomized 1,754 patients worldwide. Participants will be followed for a minimum of six months and maximum of two years from randomization.
Impact
MINS represents a major public health issue. There are no known efficacious therapies to manage patients suffering MINS. Dabigatran holds promise as an antithrombotic agent that can potentially prevent major thrombotic events. Omeprazole holds promise as a proton pump inhibitor that can potentially prevent major upper GI complications. This large trial will answer two crucial management questions for patients suffering MINS, and will influence future perioperative practices around the world.
Student Experience
Graduate students in the HRM program have been involved with the day-to-day global operations and management of the MANAGE trial, including training international global collaborators.
Countries
Argentina, Australia, Brazil, Canada, Colombia, Czech Republic, Denmark, Germany, India, Italy, Kenya, Peru, Philippines, Poland, South Africa, Spain, United Kingdom, United States of America
Impact
Research
Institutional Partner(s)
Community Partner(s)
Industry Partner(s)
Boehringer-Ingelheim
Key Outcomes
Publications
Sponsorship
Private
Sponsorship Details
Funded by: Boehringer-Ingelheim Trial Sponsor: Hamilton Health Sciences Corporation
